IDH2 and central nervous system cancer: In addition, according to WHO CNS5, patients older than 55 years without immunoreactivity to IDH1 R132H, with the histopathological characteristics of GBM, with other than midline location, and with no history of glioma, will be diagnosed as GBM IDH-wild-type CNS WHO grade 4 [10].